Glucocorticoids are important hormones in the regulation of metabolic homeostasis. We infused normal rats with dexamethasone given intracerebroventricularly (i.c.v.) for 3 days. This resulted in hyperphagia, hyperinsulinemia, and marked insulin resistance. Similar metabolic defects were observed following i.c.v. infusion of neuropeptide Y (NPY) in normal rats. As central dexamethasone infusion enhanced NPY content in the arcuate nucleus, it suggested that its metabolic effects are mediated by NPY. Moreover, due to the lack of effects observed in vagotomized animals, activation of the parasympathetic nervous system by central dexamethasone infusion is proposed. Glucocorticoid action is known to involve prereceptor metabolism by enzymes such as 11b-HSD-1 that converts inactive into active glucocorticoids. Mice overexpressing 11b-HSD-1 in adipose tissue were shown to be obese and insulin resistant. We recently observed that adipose tissue 11b-HSD-1 mRNA expression is increased at the onset of high-fat diet-induced obesity and positively correlated with the degree of hyperglycemia. In human obesity, increased adipose tissue 11b-HSD-1 expression and activity were also reported. Resistin is a new adipose tissue-secreted hormone shown to play a role in glucose homeostasis by increasing hepatic glucose production and inhibiting muscle and adipose tissue glucose utilization. We observed increased adipose tissue resistin expression in the early phase of highfat diet-induced obesity as well as decreased resistin expression in response to leptin. A positive correlation between glycemia and adipose tissue resistin expression further suggested a role of this hormone in the development of insulin resistance. The melanocortin system is another important player in the regulation of energy balance. Peripheral administration of a melanocortin agonist decreased food intake and body weight and favored lipid oxidation, effects that were more marked in obese than in lean rats. It is proposed that both resistin and melanocortin agonists may influence adipose tissue 11b-HSD-1, thereby decreasing or enhancing glucose metabolism.
Introduction
Energy homeostasis is maintained through the existence of several interactions linking the central nervous system (CNS) to peripheral tissues, and comprising afferent signal hormones from peripheral organs, the best examples so far being insulin, leptin, and ghrelin (for reviews, see Schwartz et al, 1 Rohner-Jeanrenaud, 2 Niswender and Schwartz, 3 and
Muccioli et al . These hormones act on hypothalamic neuropeptide targets to regulate food intake and modulate peripheral metabolism, via the efferent part of the autonomic nervous system. Some of these hypothalamic neuropeptides are 'anabolic', stimulating food intake and decreasing energy expenditure, while others are 'catabolic' with opposite effects. Insulin and leptin act by decreasing 'anabolic' and increasing 'catabolic' neuropeptides, while ghrelin has opposite effects within the hypothalamus (for reviews, see Schwartz et al, 1 Rohner-Jeanrenaud, 2 Niswender and Schwartz, 3 and Muccioli et al . Glucocorticoids are hormones that are well known for their direct peripheral metabolic effects, being in addition important players in the CNS-periphery relationships. This latter aspect of glucocorticoid effects, together with data on adipose tissue resistin and on the hypothalamic melanocortin system, will be presented in the present review, and be based on our own results, as well as on some of the literature.
Glucocorticoids and neuropeptide Y
Glucocorticoids are important hormones that not only exert direct catabolic peripheral effects but also modulate the synthesis and release of hypothalamic neuropeptides, thereby influencing food intake and autonomic nervous systemmediated processes. The activity of the hypothalamopituitary-adrenal axis (HPA) is reportedly increased in rodent and human obesity. Thus, in the genetically obese fa/fa rat, plasma corticosterone levels were shown to be elevated in response to stress or to feeding, while such was not always the case in the basal state, depending on both the sex and the timing of the sample within the circadian rhythm (Plotsky et al, 5 Walker et al, 6 Pacak et al, 7 Havel et al, 8 Richard et al, 9 Timofeeva and Richard, 10 Timofeeva et al, 11 Livingstone et al, 12, 13 unpublished personal observation). In these rats, urinary excretion of corticosterone metabolites was increased 12, 14, 15 and their adrenal glands were hyperplastic. 5, 8, 12, 13 These defects were partly attributed to impaired negative feedback control of the HPA axis, due to lower levels of mineralocorticoid (MR) receptors in the hippocampus but unchanged number of glucocorticoid receptors (GR). 16 MR receptors appear to be more influential during stress than in the basal state. 16 In human obesity, basal plasma cortisol levels are not consistently elevated as they are in Cushing's syndrome.
However, recent studies demonstrate that the total cortisol production rate is somewhat enhanced in obesity, in men as well as in women. [17] [18] [19] This is further supported by evidences
showing that the HPA axis responsiveness to stimuli such as acute stress, CRH/AVP, 20 adrenergic manipulations, 21 hypoglycemia, or a standard meal 22, 23 is enhanced in idiopathic obesity, particularly in visceral obesity. 21 The mild increase in glucocorticoid production and exaggerated cortisol responses in obesity can be explained by increased forward drive to the HPA axis, 24 and/or by reduced sensitivity to HPA axis feedback. [25] [26] [27] Another alternative to explain the enhanced HPA activity in obesity could involve increased peripheral tissue sensitivity to glucocorticoids. In this respect, it is interesting to note that skeletal muscle GR mRNA was reported to correlate with insulin resistance and hypertension in obesity. 28, 29 Finally, a further argument in favor of the importance of an increased HPA activity in obesity syndromes is that adrenalectomy was shown to normalize many of the behavioral and metabolic parameters of genetically obese mice, such as the ob/ob and db/db mice. 30 We studied the importance of glucocorticoids in the development of obesity by infusing normal rats with dexamethasone given intracerebroventricularly (i.c.v.) for 3 days. 31 Such central dexamethasone infusion resulted in a marked increase in food intake and body weight relative to controls. In centrally dexamethasone-infused rats, corticosterone output was completely abolished, while a state of hyperinsulinemia, hyperleptinemia, and hypertriglyceridemia was noted, and was accompanied by pronounced decreases in the expression of uncoupling protein-1 and -3 (UCP1, -3) in brown adipose tissue (BAT), as well as of UCP3 in muscle. Central dexamethasone infusion produced definite decreases in hypothalamic CRH content and increases in neuropeptide Y (NPY) in the arcuate nucleus. 31 We conducted a further study on the metabolic consequences of central dexamethasone infusion in normal rats. The aims were to determine whether increased body weight, food intake, and insulinemia resulting from intracerebroventricular dexamethasone infusion in normal rats were associated with changes in overall and tissue-specific glucose metabolism during euglycemic-hyperinsulinemic clamps associated with the labeled 2-deoxy glucose technique. 32 Involvement of the parasympathetic nervous system in the overall central effects of glucocorticoids was also assessed by studying vagotomized animals. Continuous central dexamethasone infusion for 2 days in normal rats produced a state of insulin resistance (decreased rate of glucose disappearance, Rd) due to decreased insulin-stimulated glucose utilization indices by all the muscle types studied. Furthermore, none of these alterations was observed when central glucocorticoid infusion was carried out in vagotomized animals. 32 These data together show that central glucocorticoids produce the salient hormono-metabolic alterations of obesity syndromes, such as hyperinsulinemia, increased fat deposition and insulin resistance, as summarized in Table 1 . 31, 32 Such effects are centrally elicited, mainly via an increase in hypothalamic NPY levels resulting in an activation of the parasympathetic nervous system. 31, 32 Results similar to those observed in response to i.c.v. dexamethasone infusion were obtained upon chronic central NPY administration in normal rats. Thus, and as summarized in Table 1 , which compares the effects of i.c.v NPY to those of i.c.v. dexamethasone administration, i.c.v. NPY administration for 7 days in normal rats resulted in marked hyperphagia, hyperinsulinemia, and hypercorticism, in increased fat deposition due to enhanced liver and adipose tissue de novo lipogenesis and due to increased lipoprotein lipase activity, and muscle insulin resistance. [33] [34] [35] When carried out in adrenalectomized rats, central NPY administration was shown not to have any of these metabolic effects. 36 Intracerebroventricular administration of glucocorticoids completely restored all NPY actions, indicating the requirement of these hormones for NPY induction of obesity/insulin resistance and its accompanying metabolic defects. 37 Until recently, it was believed that the sole determinants of corticosteroid action were levels of steroid hormones in the blood as modified by binding to plasma proteins (notably, corticosteroid binding globulin, CBG), and the densities of intracellular receptors in target organs. However, it has become apparent that prereceptor metabolism by 11b-hydroxysteroid dehydrogenases (11b-HSDs) potently regulates glucocorticoid access to receptors in some tissues, including the brain. 11b-HSDs catalyze the interconversion between active glucocorticoids (cortisol, corticosterone) and their inert 11-keto forms (cortisone, 11-dehydrocorticosterone, 11-DHC). 11b-HSD type 1 (11b-HSD-1) is an NADP(H)-dependent isoenzyme, predominantly acting as a reductase in vivo, converting inactive into active glucocorticoids (for a review, see, Seckl et al 38 ). It is expressed in most peripheral tissues, as well as in hippocampal neurons, 39, 40 and in neurons of the arcuate and paraventricular hypothalamic nuclei. 39, 41 11b-HSD type 2 (11b-HSD-2) is a potent NADdependent 11b-dehydrogenase, mostly present in the kidney where it rapidly inactivates glucocorticoids. Its main function is to allow aldosterone access to MRs in the distal nephron, in the face of a large molar excess of circulating glucocorticoids. 42, 43 In this review, 11b-HSD-1 only will be considered. Its main physiological and pathological roles stem from studies carried out in genetically altered mice and are summarized by part of Figure 1 . 11b-HSD-1 knockout mice showed improved glucose tolerance, impaired induction of hepatic gluconeogenic enzymes (PEPCK, glucose-6-phosphatase) during fasting, and a reduced glycemic response to stress or induction of obesity. 44 On the contrary, mice overexpressing 11b-HSD-1 selectively in adipose tissue (aP2-11b-HSD-1 transgenic mice) were shown to be moderately obese, with a more than three-fold increase in the mesenteric fat depot, and to develop glucose intolerance and insulin resistance, features that were both exacerbated by high-fat feeding. 45 These animals also exhibited dyslipidemia with elevated FFA and triglyceride levels. 45 Furthermore, angiotensinogen mRNA, which is expressed at low levels in adipose tissue, was strikingly elevated in adipose tissue of aP2-11b-HSD-1 transgenic mice. 46 This observation is likely to explain the marked hypertension seen in these animals. Finally, the animals exhibited a hyperphagia that may result from their leptin resistance (ie elevated leptin levels in the face of hyperphagia). As a general conclusion, it appears that the aP2-11b-HSD-1 transgenic mouse reproduces the main features of the metabolic syndrome. 46 When considering a potential role for 11b-HSD-1 in the development of obesity, it is of interest to mention that genetically obese Zucker rats have decreased 11b-HSD-1 expression and activity in the liver, but increased 11b-HSD-1 in omental adipose tissue. 12 Obese Zucker rats also exhibited reduced 11b-HSD-1 expression in the hippocampus. 16 Such reduced hippocampal expression of 11b-HSD-1 may be responsible for the reduced sensitivity to glucocorticoid feedback inhibition of the HPA axis, and the resulting hypercorticosteronemia mentioned above. We recently observed that adipose tissue 11b-HSD-1 mRNA expression is increased at the very onset of high-fat diet induced obesity in mice (ie at day 2), and that this increase is positively correlated with the degree of hyperglycemia. In humans, although the conversion of cortisone to cortisol is impaired in obesity, 19, 47, 48 reflecting decreased hepatic 11b-HSD-1, in vivo and in vitro 11b-HSD-1 activity and expression were increased in subcutaneous abdominal adipose tissue. [47] [48] [49] [50] [51] [52] Whether there is a decrease in 11b-HSD-1 activity or mRNA expression in the brain of obese subjects, as is the case in genetically obese Zucker rats, is unknown.
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Resistin
The identified resistin as the adipose secretory factor or ADSF, by microarray analyses. A third group initially found resistin, which they named 'FIZZ3', as an expressed sequence tag related to a protein they found to be induced during lung inflammation known as 'found in inflammatory zone 1'. 58 Resistin is a 12.5 kDa cysteine-rich, C-terminal protein, whose mRNA expression has been predominantly observed in white adipose tissue, and to a lesser extent in the hypothalamus, the pituitary, BAT, the stomach, the large intestine, the adrenal gland and skeletal muscles, in rats.
59-61
In vitro studies showed that resistin is induced during adipocyte differentiation 53, 57, 62 and, as suggested by its signal sequence, is secreted into the media. 53 Mouse studies also showed that resistin is detectable in the serum, demonstrating that it can circulate in the blood. 53 Recently, the presence of a new alternatively spliced isoform of the rat resistin gene, named S-resistin (short resistin) was described in rat adipose tissue. 63 When carboxy-tagged with a FLAG epitope and transiently expressed in cultured cell lines, the Sresistin-FLAG construct yielded a predominant nuclear staining, suggesting that S-resistin may act as a transcriptional factor. 63 With regard to the effects of resistin, recent in vivo and in vitro studies indicated that resistin influences glucose metabolism. Thus, resistin infusion was shown to markedly increase hepatic glucose production in rats via a decreased insulin action in the liver. 64 Furthermore, other studies showed that the overexpression of resistin in transgenic rats results in impaired skeletal muscle glucose metabolism and in glucose intolerance. 65 In L6 rat muscle cells, resistin was reported to inhibit insulin-stimulated glucose uptake, without altering insulin receptor signaling, presumably by decreasing the intrinsic activity of the cell surface glucose transporters. 66 Incubation of differentiating 3T3-L1 cells with conditioned medium from resistin-transfected COScells inhibited their conversion into adipocytes, suggesting that resistin might be a feedback signal to restrict adipose tissue formation. 57 In humans, the resistin gene expression is low, being about 1/250 that of the mouse. 67 While in rodents resistin is predominantly expressed in adipocytes, peripheral blood mononuclear cells seem to be a major source of resistin in humans. 68 At the protein level, mouse and human resistin show remarkable similarities with respect to the conserved cysteine residues that are reportedly involved in the dimerization process. 69 Interestingly, resistin mRNA and protein expression were also detected in human pancreatic islets. 70 The role of resistin in humans is quite controversial.
Indeed, due to its low mRNA expression level in human adipose tissue, it was initially concluded that this molecule was unlikely to be an important factor linking human obesity to insulin resistance. [71] [72] [73] However, several recent studies reported that resistin serum levels are increased in obesity [74] [75] [76] or type 2 diabetes, 77,78 with significant correlations often being observed between resistin levels and the BMI, 75 basal glycemia, 77 insulin resistance, 75, 79, 80 C-reactive peptide, 78 and hepatic lipid content. 80 In keeping with these observations, as well as with the well-known association among central obesity, insulin resistance, and type 2 diabetes, resistin mRNA and protein expression were shown to be higher in human central adipose tissue depots compared with thigh and breast adipose tissue. 81, 82 We investigated the effects of leptin administration on adipose tissue resistin expression in insulin-resistant obese ob/ob mice. 83 We observed that adipose tissue resistin mRNA and protein expression was lower in ob/ob than in wild-type control mice, in agreement with the reduced adipocyte resistin mRNA level reported in several models of obesity. Leptin administration in ob/ob mice resulted in the improvement of insulin sensitivity that was concomitant with a further decrease in resistin gene expression. The lack of leptin effect on resistin in db/db mice indicated that the leptin inhibitory action requires the long leptin receptor isoform. We also showed in normal rats that the inhibitory effect of leptin on resistin expression is centrally mediated, as it is observed in i.c.v. leptin-infused animals in which leptinemia is not elevated, but rather decreased in proportion to the fat mass. 83 High-fat feeding in C57BL/6J wildtype mice, which is known to favor the development of obesity and insulin resistance, resulted in an increase in resistin gene expression that was of early occurrence (ie present at day 2 of high-fat feeding). 83 Interestingly, in both ob/ob and high-fat fed mice, we observed a striking positive correlation between glycemia and the resistin gene expression. 83 In conclusion, our results indicate that leptin decreases the resistin gene expression, and suggest that resistin may be involved in the regulation of glucose homeostasis. Given the resistin effects on glucose metabolism just described, and the observation of the induction of obesity and insulin resistance by selective adipose tissue 11b-HSD-1 overexpression, it can be hypothesized that resistin may partially act via a local stimulation of 11b-HSD-1, which would favor adipose tissue glucocorticoid action. As reported in the literature, this may in turn promote lipolysis with resulting increased circulating FFA levels leading to muscle insulin resistance, and increased hepatic glucose production. This hypothesis is schematized by Figure 1 .
The melanocortin system
The melanocortin system comprising peptides such as a-MSH derived from the large proopiomelanocortin (POMC) molecule is of major importance in the regulation CNS control of body fat homeostasis C Asensio et al of body weight homeostasis and defects thereof in obesity (for a review, see Ellacott and Cone 84 ). The melanocortin receptors type 3 and 4 (MC3, MC4) are expressed within the brain. Their respective agonists decrease food intake and body weight, while their respective antagonists do the opposite. The melanocortin system is a target of leptin action within the hypothalamus, leptin increasing the POMC gene expression in the arcuate nucleus. With regard to obesity, it should be noted that the knockout of the POMC gene, or targeted disruption of the MC3 and/or MC4 receptor gene in mice results in obesity, and that arcuate nucleus POMC expression is decreased in obesity syndromes (for a review, see Ellacott and Cone 84 ).
We studied the effects of peripheral administration (3 days) of an MC3/MC4 agonist, MTII, in normal and genetically obese fa/fa rats. 85 MTII administration inhibited food intake and body weight, both in normal and in obese rats, the effect being more pronounced in the obese than in the lean group. Similarly, MTII prevented the food restriction-induced increase in free fatty acid (FFA) levels that was two times larger in obese than in lean animals. This MTII effect was accompanied by an enhancement in the expression of the enzyme necessary for fat oxidation, that is, carnitine palmitoyl transferase-1 (CPT-1) in the liver and adipose tissue, in both lean and obese fa/fa rats. In normal rats, food restriction resulted in marked decreases in the expression of BAT uncoupling protein 1,2, and 3 (UCP1,2,3), and of muscle UCP3. Such decreases were prevented by MTII, indicating that the energy dissipation as heat (as mediated at least by BAT UCP1) was favored by the melanocortin agonist. In obese animals, BAT UCP1,2,3 expression was low. In these animals, MTII specifically and markedly enhanced BAT and muscle UCP3, but was without any effect on BAT UCP1 and UCP2. 85 Together, these data show that MTII not only decreases food intake and body weight but also favors lipid oxidation and, putatively (ie based on data of BAT UCP1 expression) increases energy dissipation as heat. The larger effect of MTII in the obese than in the lean group suggests the presence, in obese animals, of a reduced melanocortin tone, a hypothesis that fits with the report of an increased brain MC4 receptor density in obese animals. 86 As genetically obese rodents are markedly leptin resistant, the present data also show that the melanocortin agonist, MTII, succeeds in by-passing the leptin resistance, an observation that may have pharmacological relevance for the treatment of obesity in humans.
Finally, given the observations that the melanocortin agonist is active when given peripherally, 85, 87 and that the activation of the melanocortin system was reported to improve insulin sensitivity in genetically obese Zucker rats, 88 it may be proposed that MTII could partially act by downregulating adipose tissue 11b-HSD-1. This view is schematized in Figure 1 , and is an attempt at reconciling most of the above-mentioned observations into a unitarian hypothesis centered on the role of adipose tissue 11b-HSD-1 in the regulation of metabolic homeostasis.
